Circulating microRNA profiles based on direct S‐Poly(T)Plus assay for detection of coronary heart disease

Abstract

Coronary heart disease (CHD) is one of the leading causes of heart‐associated deaths worldwide. Conventional diagnostic techniques are ineffective and insufficient to diagnose CHD with higher accuracy. To use the circulating microRNAs (miRNAs) as non‐invasive, specific and sensitive biomarkers for diagnosing of CHD, 203 patients with CHD and 144 age‐matched controls (126 high‐risk controls and 18 healthy volunteers) were enrolled in this study. The direct S‐Poly(T)Plus method was used to identify novel miRNAs expression profile of CHD patients and to evaluate their clinical diagnostic value. This method is an RNA extraction‐free and robust quantification method, which simplifies procedures, reduces variations, in particular increases the accuracy. Twelve differentially expressed miRNAs between CHD patients and high‐risk controls were selected, and their performances were evaluated in validation set‐1 with 96 plasma samples. Finally, six (miR‐15b‐5p, miR‐29c‐3p, miR‐199a‐3p, miR‐320e, miR‐361‐5p and miR‐378b) of these 12 miRNAs were verified in validation set‐2 with a sensitivity of 92.8% and a specificity of 89.5%, and the AUC was 0.971 (95% confidence interval, 0.948‐0.993, P < .001) in a large cohort for CHD patients diagnosis. Plasma fractionation indicated that only a small amount of miRNAs were assembled into EVs. Direct S‐Poly(T)Plus method could be used for disease diagnosis and 12 unique miRNAs could be used for diagnosis of CHD.

The role of miR-320 in glucose and lipid metabolism disorder-associated diseases

“…Mechanically, we found that SP1 could transcriptionally up-regulate hsa-miR-320a expression in endothelium cell [16]. Recently, Su et al profiled miRNAs in the plasma from 203 patients with CHD and 144 age-matched controls (126 high-risk controls and 18 healthy volunteers) and showed that miR-320e was increased in CHD patients [54]. Moreover, correlation analysis indicated that miR-320e could be a better biomarker for CHD diagnosis compared to most conventional clinical factors, such as apolipoprotein A (ApoA), apolipoprotein B (ApoB), and LPA [54].…”

“…Recently, Su et al profiled miRNAs in the plasma from 203 patients with CHD and 144 age-matched controls (126 high-risk controls and 18 healthy volunteers) and showed that miR-320e was increased in CHD patients [54]. Moreover, correlation analysis indicated that miR-320e could be a better biomarker for CHD diagnosis compared to most conventional clinical factors, such as apolipoprotein A (ApoA), apolipoprotein B (ApoB), and LPA [54]. Meanwhile, Liu et al also performed miRNA microarray analysis in an OPG −/− mouse model to identify miRNAs involved in vascular calcification, a major characteristic of atherosclerosis [55].…”

Dysregulation of serum miR-361-5p serves as a biomarker to predict disease onset and short-term prognosis in acute coronary syndrome patients

“…The data from this study were consistent with previous studies. For example, a significant increase in miR-361-5p expression was also found in CHD patients compared with that in highrisk controls [22]. Wang et al found that miR-361-5p was significantly increased in AMI disease patients compared to that in healthy volunteers [23].…”

Liquid Biopsy for Cancer Cachexia: Focus on Muscle-Derived microRNAs

“…Most of these skeletal muscle-derived miRNAs have also been detected in the bloodstream [40,[183][184][185][186][187][188][189][190][191][192][193][194][195][196][197][198][199]. However, to date it is unknown whether their circulating levels are modulated during cancer cachexia in humans.…”